Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.
Viking Therapeutics (NASDAQ: VKTX) announced the presentation of promising preclinical data on novel dual agonists targeting GLP-1 and GIP receptors at ObesityWeek 2021, occurring from November 1-5, 2021. Results from studies in diet-induced obese mice highlight significant weight loss and improved metabolic profiles. The poster presentations will be led by Kader Yagiz, Ph.D. This research could enhance Viking's pipeline of therapies for metabolic and endocrine disorders, further supporting its clinical programs, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The virtual presentation is scheduled for 11:00 – 11:20 a.m. Eastern. Viking is focused on developing innovative therapies for metabolic and endocrine disorders, including VK2809, a selective thyroid hormone receptor beta agonist currently in Phase 2b for NASH. The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in four upcoming investor conferences. The events include Citi's 16th Annual Biopharma Virtual Conference (Sept 8-10), H.C. Wainwright's 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 27-30). Presentations will be available online, and webcasts will follow. Viking focuses on innovative therapies for metabolic disorders, with key programs including VK2809 and VK0214 currently in clinical trials.
Viking Therapeutics (VKTX) reported its second-quarter 2021 financial results, showing a net loss of $15.4 million or $0.20 per share, up from $9.6 million or $0.13 per share in Q2 2020. The firm is advancing its clinical programs, including VK2809 for NASH, with promising interim results. The Phase 1 study of VK0214 in healthy volunteers met its primary objectives, leading to the initiation of a Phase 1b trial for X-ALD patients. Viking ended the quarter with a strong cash position of $228.3 million, supporting its ongoing studies and upcoming milestones.
Viking Therapeutics (NASDAQ: VKTX) will announce its second quarter 2021 financial results after the market close on July 28, 2021. A conference call will follow at 4:30 p.m. Eastern Time, where the company will discuss the results and corporate updates. Investors can participate by calling designated numbers or listening via webcast. Viking focuses on developing innovative therapies for metabolic and endocrine disorders, with programs including VK2809 for non-alcoholic steatohepatitis and VK0214 for X-linked adrenoleukodystrophy.
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 1b clinical trial for VK0214, a novel thyroid hormone receptor beta agonist, aimed at treating X-linked adrenoleukodystrophy (X-ALD). The trial, which is randomized and double-blind, targets adult male patients with the adrenomyeloneuropathy form of X-ALD. Key objectives include evaluating VK0214's safety, tolerability over 28 days, and its efficacy in lowering plasma levels of very long-chain fatty acids. VK0214, having completed an earlier successful Phase 1 study, has shown promising safety and pharmacokinetics.
Viking Therapeutics (NASDAQ: VKTX) announced positive results from its Phase 1 clinical trial of VK0214, a thyroid receptor beta agonist targeting X-linked adrenoleukodystrophy (X-ALD). The study confirmed VK0214's safety and tolerability with no serious adverse events and a favorable pharmacokinetic profile. Notably, VK0214 significantly reduced low-density lipoprotein cholesterol (LDL-C), triglycerides, and apolipoprotein B, indicating potential therapeutic benefits. Viking plans to commence a Phase 1b study in X-ALD patients soon.
Viking Therapeutics (NASDAQ: VKTX), a biopharmaceutical company focused on therapies for metabolic disorders, will participate in two upcoming investor conferences. On June 17, 2021, Viking will engage in 1-on-1 meetings at the SVB Leerink CybeRx Series: Liver Disease Day. Following that, from June 21-23, 2021, they will host a panel discussion on June 23 at 12:00 p.m. Eastern during the Raymond James Human Health Innovations Conference. Viking is also developing innovative drugs like VK2809 for NASH and VK0214 for X-ALD, aiming to enhance patient outcomes.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported its financial results for Q1 2021, revealing a net loss of $14.0 million, or $0.19 per share, compared to a $9.7 million loss in Q1 2020. The company continues its Phase 2b VOYAGE trial for VK2809 in NASH, with enrollment expected to complete in H2 2021. The cash balance stands at approximately $242 million, providing a strong runway for its clinical programs. Key advancements include ongoing trials for VK0214, aimed at treating X-ALD, with a Phase 1b study anticipated this summer.